SNGX - Soligenix requests FDA meeting to review study design for cancer treatment
2023-04-24 09:25:20 ET
- Soligeni ( NASDAQ: SNGX ) is trading 12% higher premarket after it said it had submitted a meeting request to the U.S. Food and Drug Administration to begin discussions regarding the design of a second, Phase 3 trial testing HyBryte to treat a rare cancer, early stage cutaneous T-cell lymphoma.
- The first Phase 3 clinical trial demonstrated statistically significant results, the company said.
- The meeting would take place about 30 days from the FDA's receipt of meeting request.
- Press Release
For further details see:
Soligenix requests FDA meeting to review study design for cancer treatment